| Patient | Satchel Paige |
|---|---|
| Date of birth | 1953-07-07 |
| Identifiers | MRN HR-ML047-SYN; SSN (made up) 000-47-3381 |
| Document date | 2026-07-28 |
| Author | Delphine Whitaker-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review on the day of the pulmonology consultation. [S]
Mr. Paige returns two weeks after intake and was seen this morning by Dr. Lindqvist-Bello of pulmonology, who did spirometry before and after albuterol, an arterial blood gas and a six-minute walk. He uses his albuterol once or twice a day, mostly before walking to the store, with the spacer. He is still breathless after one flight of stairs or a block on the level and coughs up a little clear sputum each morning. He has had no flare-ups in the past year. He takes atorvastatin each evening without muscle aches. He asked to see his breathing numbers and how they were worked out, and said he had read that lung tests used to be scored differently for Black patients; Dr. Lindqvist-Bello went through the results with him. [S]
| Element | Detail |
|---|---|
| Spirometry | Post-bronchodilator FEV1 2.02 L, FVC 3.48 L, FEV1/FVC 0.58; FEV1 61% predicted (GLI Global) |
| Blood gas | pH 7.42, PaCO2 40, PaO2 70 mm Hg on room air |
| Six-minute walk | 360 m; lowest saturation 90 percent |
| Symptoms | CAT 18; mMRC 2 |
| Exacerbations | None in the past year |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless after a block; morning cough with a little clear sputum; no wheeze at rest or hemoptysis |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea or ankle swelling |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness | Two inhalations with a spacer every 4 hours as needed | Respiratory tract route | 2026-07-14 | active | S |
| Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day | One inhalation each morning; a strong, deep breath in | Respiratory tract route | 2026-07-28 | active | S |
| Atorvastatin 20 mg tablet once a day | One tablet each evening | Oral route | 2026-07-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-28 | Body height | 191 | cm | S |
| 2026-07-28 | Body weight | 82.4 | kg | S |
| 2026-07-28 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-07-28 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-07-28 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-28 | Heart rate | 82 | /min | S |
| 2026-07-28 | Respiratory rate | 18 | /min | S |
| 2026-07-28 | Body temperature | 36.6 | Cel | S |
| 2026-07-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-28 | FEV1 --pre bronchodilation | 1.92 | L | Lower limit of normal, GLI Global (race-neutral) for age, sex and height | Low | S |
| 2026-07-28 | FEV1 --post bronchodilation | 2.02 | L | Lower limit of normal, GLI Global (race-neutral) | Low | S |
| 2026-07-28 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 3.48 | L | Lower limit of normal, GLI Global (race-neutral) | Normal | S |
| 2026-07-28 | FEV1/FVC --post bronchodilation | 0.58 | {ratio} | GOLD fixed ratio 0.70; post-bronchodilator ratio below 0.70 confirms airflow obstruction (GLI Global lower limit of normal about 0.62) | Low | S |
| 2026-07-28 | FEV1 measured/predicted | 61 | % | GOLD grade 1 at 80% or more, grade 2 at 50 to 79% | Low | S |
| 2026-07-28 | pH of Arterial blood | 7.42 | [pH] | 7.35-7.45 [pH] | Normal | S |
| 2026-07-28 | Carbon dioxide [Partial pressure] in Arterial blood | 40 | mm[Hg] | 35-45 mmHg | Normal | S |
| 2026-07-28 | Oxygen [Partial pressure] in Arterial blood | 70 | mm[Hg] | Long-term oxygen threshold: 55 mm Hg or less (60 or less with cor pulmonale or polycythemia) | Low | S |
| 2026-07-28 | Six minute walk test | 360 | m | Predicted about 520 m for his age, sex and height; lower limit about 400 m | Low | S |
Vital signs recorded on 2026-07-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tall and lean; talks in full sentences; blood pressure 132/80, pulse 82, oxygen saturation 94 percent on room air |
| Respiratory | Barrel-shaped chest; reduced breath sounds throughout; prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm; heart sounds soft; no edema |
| Inhaler technique | Albuterol with spacer correct; dry powder inhaler technique taught with a placebo device, with a strong, deep breath in, and repeated back correctly |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD. |
| Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysema | active | confirmed | J44.9 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic. |
| Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use since | active | confirmed | Z87.891 | S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such. |
| Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decision | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Spirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global) | At diagnosis, then at least yearly or with a clear change | Completed today | FEV1 1.92 L before and 2.02 L after albuterol; FVC 3.48 L; FEV1/FVC 0.58; FEV1 61% predicted by GLI Global: obstruction, GOLD grade 2 |
| Examination | Pulse oximetry at rest | Every visit | Completed today | 94 percent on room air, read with the knowledge that oximetry can overestimate saturation in darker skin |
| Laboratory | Arterial blood gas | When saturation is 92 percent or less, for oxygen assessment, or when oximetry may be unreliable | Completed today | Done because his oximetry may overstate his oxygen level: pH 7.42, PaCO2 40, PaO2 70 mm Hg |
| Survey | Symptoms: CAT and mMRC dyspnea scale | Every visit | Completed today | CAT 18; mMRC 2 (no LOINC survey code; recorded in the note) |
| Survey | Exacerbations in the past 12 months (moderate and severe) and GOLD group | Every visit | Completed today | None in the past year; GOLD group B |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker, about 30 pack-years, stopped eleven years ago |
| Examination | BMI and nutrition | Every visit | Completed today | BMI 22.6; weight steady |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Up to date | 0.08 x 10^3/uL at intake: argues against an inhaled corticosteroid |
| Laboratory | Alpha-1 antitrypsin | Once, at diagnosis | Up to date | 142 mg/dL at intake, normal |
| Medication safety | Inhaler technique, adherence and side effects (dry mouth, urinary retention) | Every visit | Completed today | Spacer technique correct; dry powder inhaler taught today with a placebo device |
| Examination | ECG and cardiovascular risk | At baseline; reassess after exacerbations | Up to date | ECG normal and NT-proBNP 92 pg/mL at intake |
| Self-management | Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zoster | Yearly review | Completed today | PCV20 and Tdap at intake; influenza, RSV and COVID-19 due in the autumn; zoster to be given then |
| Imaging | Low-dose CT lung cancer screening | Yearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quitting | Ordered | Eligible (73, about 30 pack-years, stopped eleven years ago); chose screening after shared decision-making; booked in one week |
| Referral | Pulmonary rehabilitation | Offer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbation | Referred | mMRC 2 and CAT 18; program twice a week from the second week of August; a church volunteer will drive him |
| Examination | Six-minute walk test | At rehabilitation entry and exit, and for oxygen assessment | Completed today | 360 m on room air; lowest saturation 90 percent |
| Examination | Long-term oxygen assessment | When resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twice | Not indicated | PaO2 70 mm Hg at rest and lowest walking saturation 90 percent: no long-term or ambulatory oxygen (moderate desaturation, LOTT) |
| Self-management | Written and spoken COPD action plan | At diagnosis, reviewed after each exacerbation | Completed today | Explained aloud and given in writing: daily inhaler, when to use the reliever, call the clinic the same day for more breathlessness or a change in sputum, call 911 for breathlessness at rest, chest pain or confusion |
| Medication safety | Statin safety: muscle symptoms | Every visit | Completed today | No muscle aches |
| Referral | Pulmonology consultation | At diagnosis | Completed today | Seen by Dr. Lindqvist-Bello today |
Goal progress:
Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020); Lung Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)
Follow-up: Start the new inhaler tomorrow morning. Low-dose CT in one week. Rehabilitation from the second week of August. Eight-week review with a lipid panel. Next scheduled visit 2026-09-08: eight-week review: symptoms on the new inhaler, technique, rehabilitation, the screening CT and the lipid response. [S]